Product Description
Alvocidib is a synthetic dihydroxyflavone that is 5,7-dihydroxyflavone which is substituted by a 3-hydroxy-1-methylpiperidin-4-yl group at position 8 and by a chlorine at the 2' position (the (-)-3S,4R stereoisomer). A cyclin-dependent kinase 9 (CDK9) inhibitor, it has been studied for the treatment of acute myeloid leukaemia, arthritis and atherosclerotic plaque formation. It has a role as an antineoplastic agent, an EC 2.7.11.22 (cyclin-dependent kinase) inhibitor, an antirheumatic drug and an apoptosis inducer. It is a dihydroxyflavone, a hydroxypiperidine, a member of monochlorobenzenes and a tertiary amino compound. It is a conjugate base of an alvocidib(1+). (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Alvocidib)
Mechanisms of Action: CDK9 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Chronic Lymphoid Leukemia|Prolymphocytic B-Cell Leukemia|Lymphocytic Chronic B-Cell Leukemia|Prolymphocytic Leukemia|Mantle-Cell Lymphoma|Esophageal Cancer|Kidney Cancer|Breast Cancer|Acute Myeloid Leukemia|Pancreatic Cancer|Renal Cell Carcinoma|Melanoma|Multiple Myeloma|Adenocarcinoma|Diffuse Large B-Cell Lymphoma|Hypereosinophilic Syndrome|Sarcoma|Waldenstrom Macroglobulinemia|Acute Erythroblastic Leukemia|Germinoma|Testicular Cancer|Lymphoma, B-Cell|Acute Monocytic Leukemia|Acute Basophilic Leukemia|Acute Megakaryoblastic Leukemia|Acute Eosinophilic Leukemia|Seminoma|Acute Myelomonocytic Leukemia|Lymphoma, Non-Hodgkin|Prostate Cancer|Ovarian Cancer|Head and Neck Cancer|Large-Cell Anaplastic Lymphoma|Large-Cell Immunoblastic Lymphoma|Immunoblastic Lymphadenopathy|Mycosis Fungoides|Leukemia, Plasma Cell|Adult T-Cell Leukemia-Lymphoma|Follicular Lymphoma|Endometrial Cancer|Sezary Syndrome|Thromboembolism|Liver Cancer|Squamous Cell Carcinoma|T-Cell Cutaneous Lymphoma|Myelodysplastic Syndrome|Peritoneal Cancer|Multiple Sclerosis|Acute Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Gastrointestinal Cancer|B-Cell Marginal Zone Lymphoma|Preleukemia|Lymphomatoid Granulomatosis
Phase 1: Medulloblastoma|Neuroblastoma|Wilms Tumor|Brain Stem Cancer|Kidney Cancer|Breast Cancer|Melanoma|Mantle-Cell Lymphoma|Follicular Lymphoma|Acute Lymphoid Leukemia|Chronic Myelomonocytic Leukemia|Acute Myeloid Leukemia|Acute Megakaryoblastic Leukemia|Oncology Solid Tumor Unspecified|Non-Small-Cell Lung Cancer|Lymphoma, Non-Hodgkin|Embryonal Rhabdomyosarcoma|Waldenstrom Macroglobulinemia|Gastrointestinal Stromal Tumors|Acute Erythroblastic Leukemia|Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia|Sarcoma|Thrombocytopenia|Anemia, Refractory|Diffuse Large B-Cell Lymphoma|Astrocytoma|Hypothalamic Cancer|Optic Nerve Cancer|Osteosarcoma|Cerebellar Cancer|Prostate Cancer|Pancreatic Cancer|Intestinal Cancer|Primitive Neuroectodermal Tumors|Liver Cancer|Lymphoid Leukemia|Soft Tissue Cancer|Optic Nerve Glioma|Supratentorial Cancer|Kidney Diseases|Peripheral Neuroectodermal Tumors, Primitive|Ependymoma|Retinoblastoma|Sarcoma, Ewing|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Acute Monocytic Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Skin Cancer|Chronic Myeloid Leukemia|Adenocarcinoma|Acute Basophilic Leukemia|Multiple Myeloma|B-Cell Marginal Zone Lymphoma|Acute Eosinophilic Leukemia|Lymphoma|Blast Crisis|Prolymphocytic Leukemia|Acute Myelomonocytic Leukemia|Hypereosinophilic Syndrome|Anemia, Refractory, with Excess of Blasts|Prolymphocytic B-Cell Leukemia|Lymphoma, B-Cell|Mesothelioma|Leukemia|Esophageal Cancer|Oncology Hematological Unspecified|Male Breast Cancer|Lymphoproliferative Disorders|Hairy Cell Leukemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2017-001178-41 | P2 |
Terminated |
Acute Myeloid Leukemia |
2021-10-10 |
|
| TPI-ALV-102 | P2 |
Terminated |
Preleukemia|Myelodysplastic Syndrome |
2021-08-16 |
|
| TPI-ALV-202 | P2 |
Terminated |
Acute Myeloid Leukemia |
2021-04-22 |
|
| M16-186 | P1 |
Completed |
Acute Myeloid Leukemia |
2021-01-25 |
41% |